NEW ANTIBIOTICS, NEED OF THE HOUR: IDSA
The pharmaceutical companies have been urged to produce more antibiotics by the Infectious Diseases Society of America (IDSA). The federal legislation is being encouraged to provide drug companies with incentives to do so. Combating the drug-resistant microbes should deserve the utmost priority owing to the health risks involved. No anti-biotics have so far been developed to treat such life-threatening infections. The pathogenic organisms against which effective drugs have to be developed include methicillin-resistant staphylococcus aureus, E-coli, acinetobacter baumannii, klebsiella, vancomycin-resistant enterococcus faecium pseudomonas aeruginosa and aspergillus.